CerMed’s three initial products are based on four core technologies, three of which are essential to the development of the proprietary platform test system which provides a highly sensitive, rapid, easy to use, point of care diagnostic tool. The first product will screen cervical cells for cancer using a combination of four biomarkers in conjunction with it’s microfluidic cartridge employing a micro-electrode array.

CerMed has a strong technology and patent position through its own efforts as well as through in-licensed technology and OEM product development agreements. In total, CerMed products will be protected by at least 11 patents: 4 patents issued, 4 patents pending, and 3 under preparation. It is anticipated that additional patents will be applied for as the novel products are finalized and then expanded to include additional applications.

CerMed Intellectual Property